64693-47-6

Usage

InChI:InChI=1/C10H13NO/c1-3-11(2)10-6-4-9(8-12)5-7-10/h4-8H,3H2,1-2H3

Upstream product

• 100-97-0 hexamethylenetetramine 
• 613-97-8 N-methyl-N-ethylaniline 
• 68-12-2 N,N-dimethyl-formamide 
• 624-78-2 N-Ethylmethylamine 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 119187-32-5 N-ethyl-4-(trans-2-[4]quinolyl-vinyl)-N-methyl-aniline 
• 94682-39-0 N,N'-diethyl-N,N'-dimethyl-trans-stilbene-4,4'-diyldiamine 
• 95548-98-4 (E)-2,3-Bis-[4-(ethyl-methyl-amino)-phenyl]-but-2-enedinitrile 
• 95549-03-4 2,3-Bis-[4-(ethyl-methyl-amino)-phenyl]-succinonitrile 
• 1402063-12-0 2-(4-(ethyl(methyl)amino)benzylidene)-5,6-dihydroxy-2,3-dihydro-1H-inden-1-one 4-methylbenzene-1-sulfonic acid 
• 1402063-05-1 2-(4-(ethyl(methyl)amino)benzylidene)-6-hydroxy-5-methoxy-2,3-dihydro-1H-inden-1-one hydrochloride 
• 1333325-69-1 1,3,5,7-tetramethyl-2,6-bis(2-methoxycarbonylethyl)-8-[4-(N-ethyl-N-methylamino)phenyl]-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
• 1333325-70-4 1,3,5,7-tetramethyl-2,6-bis(2-carboxyethyl)-8-[4-(N-ethyl-N-methylamino)phenyl]-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
• 1333325-62-4 C₄₀H₅₃BF₂N₈O₈ 

Relevant academic research and scientific papers

Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease

A series of indanone derivatives were designed, synthesized, and tested using a variety of assays to assess their potential as anti-Alzheimer's disease (AD) agents. The investigations assessed the activities of the agents for the inhibition of cholinesterases (AChE and BuChE), the inhibition of amyloid beta (Aβ) self-assembly, and the catalysis of the disassembly of preformed Aβ oligomers and measured their antioxidant activities. Our results demonstrate that most of the synthesized compounds demonstrated good inhibitory activity against AChE with IC50 values in the nanomolar range. In particular, compounds 9 (IC50 Combining double low line 14.8 nM) and 14 (IC50 Combining double low line 18.6 nM) exhibited markedly higher inhibitory activities than tacrine and similar activities to donepezil. In addition, 9 and 14 significantly inhibited Aβ aggregation (inhibition rates of 85.5% and 83.8%, respectively), catalysed the disaggregation of Aβ fibrils generated by self-induced Aβ aggregation, and exhibited antioxidant activity. Furthermore, these two compounds can cross the blood-brain barrier (BBB) in vitro. These properties highlight the potential of these new compounds to be developed as multi-functional drugs for the treatment of Alzheimer's disease.

Multitarget-directed benzylideneindanone derivatives: Anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease

A novel series of benzylideneindanone derivatives were designed, synthesized, and evaluated as multitarget-directed ligands against Alzheimer's disease. The in vitro studies showed that most of the molecules exhibited a significant ability to inhibit self-induced β-amyloid (Aβ 1-42) aggregation (10.5-80.1%, 20 μM) and MAO-B activity (IC 50 of 7.5-40.5 μM), to act as potential antioxidants (ORAC-FL value of 2.75-9.37), and to function as metal chelators. In particular, compound 41 had the greatest ability to inhibit Aβ1-42 aggregation (80.1%), and MAO-B (IC50 = 7.5 μM) was also an excellent antioxidant and metal chelator. Moreover, it is capable of inhibiting Cu(II)-induced Aβ1-42 aggregation and disassembling the well-structured Aβ fibrils. These results indicated that compound 41 is an excellent multifunctional agent for the treatment of AD.